Genetron Health's breakthrough liver cancer early screening technology was written into the "Expert Consensus on the Use of Blood Markers for Clinical Early Screening of Hepatocellular Carcinoma"

Beijing, November 2, 2021/PRNewswire/ - Recently, Genetron Health (Nasdaq: GTH), a leading global cancer precision medicine company, announced that its HCCscreenTM, an early screening product for liver cancer based on the original M2P-HCC model, has been officially launched Written into the "Expert Consensus on the Use of Blood Markers for Early Clinical Hepatocellular Carcinoma Screening" issued by the Infectious Disease Prevention and Control Branch of the Chinese Preventive Medicine Association (hereinafter referred to as the "Consensus")

The "Consensus" pointed out that it is possible to further improve the sensitivity and specificity of early HCC diagnosis through detection of cfDNA, and the focus is clearly defined.

The M2P-HCC model is derived from the HIT study.

In March 2021, the "HCCscreenTM Investigational Study" (HIT) multi-center prospective study data initiated by Genetron Health and the National Cancer Center of China showed that based on the follow-up of 1615 hepatitis B surface antigen-positive patients, the M2P-HCC model was used for HCC Screening achieves 88% sensitivity and 93% specificity, and its screening performance is better than alpha-fetoprotein (AFP) detection combined with ultrasound

Primary liver cancer has long been a public health issue that has attracted much attention

How to actively and effectively tackle liver cancer, a malignant disease that seriously threatens people's lives? A large number of clinical practices have proved that the 5-year overall survival rate of patients with early HCC (BCLC stage 0~A) ​​receiving radical treatment can be as high as 69.

In order to improve the level of liver cancer prevention and control in China, the Infectious Disease Prevention and Control Branch of the Chinese Preventive Medicine Association has gathered opinions from 15 medical experts in liver diseases, infectious diseases, oncology, epidemiology, etc.

List of experts

At the same time, under the promotion of relevant ministries and commissions, relevant institutions, mainly hospitals, are actively implementing the establishment of a three-level prevention system around liver cancer, especially focusing on secondary prevention for people with chronic liver disease, and timely control of related causes And risk factors are screened and monitored according to risk stratification to reduce or delay the occurrence of liver cancer

In addition to the application of innovative liquid biopsy technology for early screening of HCC high-risk populations, and in conjunction with secondary prevention, the "Consensus" also recommends the frequency of testing based on the risk stratification of the target population: non-high-risk populations once a year, high-risk populations Once in 6 months, once in 3 months for very high-risk groups

Genetron Health Co-founder and CEO Wang Sizhen said: "Since the first important paper published in the Proceedings of the National Academy of Sciences (PNAS) in 2019, Genetron Health has made significant progress in advancing the clinical application of HCCscreenTM

references

[1] Wang FS, Fan JG, Zhang Z, Gao B, Wang HY.

[2] Jia Xiao,Fei Wang,Nai-Kei Wong,Jinhan He,Rui Zhang,Ruijuan Sun,Yanying Xu,Yingxia Liu,Wei Li,Kazuo Koike,Weiling He,Hong You,Yinglei Miao,Xiaowei Liu,Mingming Meng, Bin Gao,Hua Wang,Cui Li.

[3] GLOBOCAN 2020 https://gco.

[4] TsilimigrasDI, BaganteF, SaharaK, et al.

[5] ParkJW, ChenM, ColomboM, et al.

Source: Genetron Health